Magaldrate

Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.

Magaldrate
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682683
Pregnancy
category
  • C
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNegligible
MetabolismNil
ExcretionFecal and renal
Identifiers
  • Magnesium aluminate monohydrate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.115.465
Chemical and physical data
FormulaAlMg2(OH)7·H2O
Molar mass212.66 g/mol
  • InChI=1S/Al.Mg.2H2O/h;;2*1H2/p-1 Y
  • Key:SXSTVPXRZQQBKQ-UHFFFAOYSA-M Y
  (verify)

Development

Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]

Available forms

Magaldrate is available in the form of oral suspension or tablets.

Pharmacology

Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]

Interactions and adverse reactions

Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.

References
  1. US patent 2923660, Hallmann G, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
  2. Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
  3. Laurence BL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.